RA Capital Management
Latest statistics and disclosures from Ra Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ASND, CDTX, RYTM, RNA, PCVX, and represent 49.01% of Ra Capital Management's stock portfolio.
- Added to shares of these 10 stocks: BCRX (+$124M), PRAX (+$110M), RYTM (+$106M), OLMA (+$65M), NUVL (+$64M), EVMN (+$59M), SYRE (+$53M), LXEO (+$50M), VOR (+$45M), CAPR (+$44M).
- Started 22 new stock positions in MDLN, SYRE, RANI, BCRX, CCCC, OLMA, RZLT, PALI, PRAX, PTN. KIDS, HNGE, OVID, ACET, EVMN, CAPR, HCAT, Qiagen Nv, WAY, GRAL, LXEO, BNTC.
- Reduced shares in these 10 stocks: ETNB (-$292M), ACLX (-$115M), CLYM (-$81M), BLTE (-$71M), PCVX (-$57M), DNTH (-$52M), FULC (-$47M), SRRK (-$44M), GPCR (-$43M), MTSR (-$35M).
- Sold out of its positions in Adicet Bio, RCUS, CTMX, ETNB, ELDN, EVH, EXAS, GKOS, LRMR, MTSR. PRME, SRRK, GPCR, SRZN, TNGX, TVTX, IFRX, QURE.
- Ra Capital Management was a net seller of stock by $-17M.
- Ra Capital Management has $9.7B in assets under management (AUM), dropping by 19.87%.
- Central Index Key (CIK): 0001346824
Tip: Access up to 7 years of quarterly data
Positions held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 71 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ascendis Pharma A/s - SH (ASND) | 22.5 | $2.2B | 10M | 213.24 |
|
|
| Cidara Therapeutics SH (CDTX) | 7.6 | $743M | 3.4M | 220.89 |
|
|
| Rhythm Pharmaceuticals SH (RYTM) | 7.3 | $714M | +17% | 6.7M | 107.04 |
|
| Avidity Biosciences SH (RNA) | 6.4 | $623M | 8.6M | 72.13 |
|
|
| Vaxcyte SH (PCVX) | 5.1 | $495M | -10% | 11M | 46.14 |
|
| Sionna Therapeutics SH (SION) | 4.2 | $408M | -5% | 9.9M | 41.14 |
|
| Newamsterdam Pharma Co Nv SH (NAMS) | 3.4 | $335M | -5% | 9.6M | 35.08 |
|
| Tyra Biosciences SH (TYRA) | 3.3 | $321M | 12M | 26.29 |
|
|
| Wave Life Sciences SH (WVE) | 3.2 | $310M | 18M | 17.00 |
|
|
| Mineralys Therapeutics SH (MLYS) | 2.7 | $266M | 7.3M | 36.29 |
|
|
| Edgewise Therapeutics SH (EWTX) | 2.7 | $259M | 10M | 24.82 |
|
|
| Septerna SH (SEPN) | 2.0 | $195M | 7.0M | 27.88 |
|
|
| Nuvalent Inc-a SH (NUVL) | 1.9 | $189M | +50% | 1.9M | 100.59 |
|
| Disc Medicine SH (IRON) | 1.6 | $157M | +25% | 2.0M | 79.41 |
|
| Janux Therapeutics SH (JANX) | 1.6 | $154M | 11M | 13.80 |
|
|
| Pepgen SH (PEPG) | 1.3 | $131M | 20M | 6.51 |
|
|
| Taysha Gene Therapies SH (TSHA) | 1.3 | $130M | 24M | 5.50 |
|
|
| Ars Pharmaceuticals SH (SPRY) | 1.3 | $127M | 11M | 11.65 |
|
|
| Biocryst Pharmaceuticals SH (BCRX) | 1.3 | $124M | NEW | 16M | 7.80 |
|
| Bicara Therapeutics SH (BCAX) | 1.2 | $117M | 7.0M | 16.83 |
|
|
| Praxis Precision Medicines I SH (PRAX) | 1.1 | $110M | NEW | 374k | 294.74 |
|
| Gh Research SH (GHRS) | 1.0 | $98M | 7.7M | 12.70 |
|
|
| Geron Corp SH (GERN) | 0.9 | $84M | +5% | 64M | 1.32 |
|
| Arcellx SH (ACLX) | 0.8 | $83M | -58% | 1.3M | 65.20 |
|
| Vor Biopharma SH (VOR) | 0.7 | $71M | +172% | 5.4M | 13.08 |
|
| Belite Bio Inc - SH (BLTE) | 0.7 | $69M | -50% | 433k | 159.96 |
|
| Fulcrum Therapeutics SH (FULC) | 0.7 | $69M | -40% | 6.1M | 11.31 |
|
| Lenz Therapeutics SH (LENZ) | 0.7 | $67M | 4.2M | 16.00 |
|
|
| Dianthus Therapeutics SH (DNTH) | 0.7 | $66M | -43% | 1.6M | 41.21 |
|
| Olema Pharmaceuticals SH (OLMA) | 0.7 | $65M | NEW | 2.6M | 25.00 |
|
| Evommune SH (EVMN) | 0.6 | $59M | NEW | 3.5M | 17.12 |
|
| Jade Biosciences SH (JBIO) | 0.6 | $57M | +245% | 3.7M | 15.43 |
|
| Spyre Therapeutics SH (SYRE) | 0.5 | $53M | NEW | 1.6M | 32.76 |
|
| Lexeo Therapeutics SH (LXEO) | 0.5 | $50M | NEW | 5.0M | 9.93 |
|
| Lb Pharmaceuticals SH (LBRX) | 0.5 | $49M | +24% | 2.2M | 22.26 |
|
| Climb Bio SH (CLYM) | 0.5 | $45M | -64% | 11M | 4.00 |
|
| Monopar Therapeutics SH (MNPR) | 0.4 | $44M | +30% | 667k | 65.30 |
|
| Capricor Therapeutics SH (CAPR) | 0.4 | $44M | NEW | 1.5M | 28.86 |
|
| 4d Molecular Therapeutics In SH (FDMT) | 0.4 | $42M | +23% | 5.7M | 7.50 |
|
| Invivyd SH (IVVD) | 0.4 | $42M | 17M | 2.47 |
|
|
| Artiva Biotherapeutics SH (ARTV) | 0.4 | $42M | 9.9M | 4.29 |
|
|
| Grail SH (GRAL) | 0.4 | $37M | NEW | 428k | 85.59 |
|
| Assembly Biosciences SH (ASMB) | 0.4 | $35M | 1.0M | 34.01 |
|
|
| Solid Biosciences SH (SLDB) | 0.3 | $33M | 5.8M | 5.64 |
|
|
| Acumen Pharmaceuticals SH (ABOS) | 0.3 | $32M | 15M | 2.11 |
|
|
| Benitec Biopharma SH (BNTC) | 0.3 | $25M | NEW | 1.9M | 13.47 |
|
| Contineum Therapeutics Inc-a SH (CTNM) | 0.3 | $25M | +2% | 2.2M | 11.43 |
|
| Rezolute SH (RZLT) | 0.2 | $22M | NEW | 9.2M | 2.36 |
|
| Acrivon Therapeutics SH (ACRV) | 0.2 | $20M | 8.3M | 2.41 |
|
|
| Nkarta SH (NKTX) | 0.2 | $20M | 11M | 1.85 |
|
|
| Ovid Therapeutics SH (OVID) | 0.2 | $18M | NEW | 11M | 1.63 |
|
| Palisade Bio SH (PALI) | 0.2 | $17M | NEW | 7.1M | 2.35 |
|
| Sab Biotherapeutics SH (SABS) | 0.2 | $17M | 4.4M | 3.74 |
|
|
| C4 Therapeutics SH (CCCC) | 0.2 | $15M | NEW | 8.0M | 1.91 |
|
| Medline Inc-cl A SH (MDLN) | 0.1 | $14M | NEW | 335k | 42.00 |
|
| Design Therapeutics SH (DSGN) | 0.1 | $14M | +207% | 1.5M | 9.38 |
|
| Inspire Medical Systems SH (INSP) | 0.1 | $13M | +23% | 142k | 92.23 |
|
| Avalo Therapeutics SH (AVTX) | 0.1 | $12M | 663k | 18.16 |
|
|
| Rani Therapeutics Holdings-a SH (RANI) | 0.1 | $12M | NEW | 8.5M | 1.35 |
|
| Perceptive Capital Solutions SH (PCSC) | 0.1 | $9.8M | 750k | 13.03 |
|
|
| Adicet Bio SH (ACET) | 0.1 | $8.0M | NEW | 948k | 8.42 |
|
| Newamsterdam Pharma Co Nv-27 SH (NAMSW) | 0.1 | $7.7M | 333k | 23.00 |
|
|
| Genedx Holdings Corp SH (WGS) | 0.1 | $7.5M | 58k | 130.06 |
|
|
| Waystar Holding Corp SH (WAY) | 0.0 | $4.7M | NEW | 144k | 32.75 |
|
| Werewolf Therapeutics SH (HOWL) | 0.0 | $4.2M | 6.7M | 0.63 |
|
|
| Hinge Health Inc-a SH (HNGE) | 0.0 | $3.7M | NEW | 80k | 46.45 |
|
| Progyny SH (PGNY) | 0.0 | $2.5M | 97k | 25.68 |
|
|
| Qiagen SH | 0.0 | $2.1M | NEW | 44k | 47.34 |
|
| Orthopediatrics Corp SH (KIDS) | 0.0 | $2.0M | NEW | 110k | 17.76 |
|
| Health Catalyst SH (HCAT) | 0.0 | $1.9M | NEW | 794k | 2.39 |
|
| Palatin Technologies SH (PTN) | 0.0 | $1.1M | NEW | 70k | 15.38 |
|
Past Filings by Ra Capital Management
SEC 13F filings are viewable for Ra Capital Management going back to 2010
- Ra Capital Management 2025 Q4 filed Feb. 17, 2026
- Ra Capital Management 2025 Q3 filed Nov. 14, 2025
- Ra Capital Management 2025 Q2 filed Aug. 14, 2025
- Ra Capital Management 2025 Q1 filed May 15, 2025
- Ra Capital Management 2024 Q4 filed Feb. 14, 2025
- Ra Capital Management 2024 Q3 filed Nov. 14, 2024
- Ra Capital Management 2024 Q2 filed Aug. 14, 2024
- Ra Capital Management 2024 Q1 amended filed May 17, 2024
- Ra Capital Management 2024 Q1 filed May 15, 2024
- Ra Capital Management 2023 Q4 filed Feb. 14, 2024
- Ra Capital Management 2023 Q3 amended filed Nov. 15, 2023
- Ra Capital Management 2023 Q3 filed Nov. 14, 2023
- Ra Capital Management 2023 Q2 filed Aug. 14, 2023
- Ra Capital Management 2023 Q1 filed May 15, 2023
- Ra Capital Management 2022 Q4 filed Feb. 14, 2023
- Ra Capital Management 2022 Q3 filed Nov. 14, 2022